You are here

Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer

Title: Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer.
17 views
5 downloads
Name(s): Vallega, Karin A., author
Liu, NingNing, author
Myers, Jennifer S., author
Yu, Kaixian, author
Sang, Qing-Xiang Amy, author
Type of Resource: text
Genre: Text
Date Issued: 2016-06-17
Physical Form: computer
online resource
Extent: 1 online resource
Language(s): English
Abstract/Description: Introduction African American (AA) women diagnosed with breast cancer are more likely to have aggressive subtypes. Investigating differentially expressed genes between patient populations may help explain racial health disparities. Resistin, one such gene, is linked to inflammation, obesity, and breast cancer risk. Previous studies indicated that resistin expression is higher in serum and tissue of AA breast cancer patients compared to Caucasian American (CA) patients. However, resistin expression levels have not been compared between AA and CA patients in a stage- and subtype-specific context. Breast cancer prognosis and treatments vary by subtype. This work investigates differential resistin gene expression in human breast cancer tissues of specific stages, receptor subtypes, and menopause statuses in AA and CA women. Methods Differential gene expression analysis was performed using human breast cancer gene expression data from The Cancer Genome Atlas. We performed inter-race resistin gene expression level comparisons looking at receptor status and stage-specific data between AA and CA samples. DESeq was run to test for differentially expressed resistin values. Results Resistin RNA was higher in AA women overall, with highest values in receptor negative subtypes. Estrogen-, progesterone-, and human epidermal growth factor receptor 2-negative groups showed statistically significant elevated resistin levels in Stage I and II AA women compared to CA women. In inter-racial comparisons, AA women had significantly higher levels of resistin regardless of menopause status. In whole population comparisons, resistin expression was higher among Stage I and III estrogen receptor negative cases. In comparisons of molecular subtypes, resistin levels were significant higher in triple negative than in luminal A breast cancer. Conclusion Resistin gene expression levels were significantly higher in receptor negative subtypes, especially estrogen receptor negative cases in AA women. Resistin may serve as an early breast cancer biomarker and possible therapeutic target for AA breast cancer.
Identifier: FSU_libsubv1_wos_000378030000048 (IID), 10.1371/journal.pone.0157741 (DOI)
Keywords: biomarker, mortality, obesity, postmenopausal women, risk
Publication Note: The publisher’s version of record is available at http://www.dx.doi.org/10.1371/journal.pone.0157741
Persistent Link to This Record: http://purl.flvc.org/fsu/fd/FSU_libsubv1_wos_000378030000048
Owner Institution: FSU
Is Part Of: Plos One.
1932-6203
Issue: iss. 6, vol. 11

Choose the citation style.
Vallega, K. A., Liu, N. N., Myers, J. S., Yu, K., & Sang, Q. -X. A. (2016). Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer. Plos One. Retrieved from http://purl.flvc.org/fsu/fd/FSU_libsubv1_wos_000378030000048